The US Biosecure Act threatens to destabilise the pharmaceutical industry
The US pharma industry relies heavily on Chinese contract manufacturers to help develop and produce its therapeutics.
Syngene WP
BIOSECURE Act could impact WuXi-manufactured drugs for the US market
US lawmakers urge administration to take action against Wuxi
Cell and gene therapies – top pharmaceutical industry trend to watch for 2024
Myricx Bio signs licence deal for WuXi Biologics’s antibody
Merck & Co bolsters neurogenerative portfolio with Caraway acquisition
Atreca downsizes again to focus on antibody-drug conjugate programmes
Eli Lilly reiterates POINT acquisition plans with tender offer extension
